Health Insurance (Pathology Services Table) Amendment Regulations 2001 (No. 4) 2001 No. 312
EXPLANATORY STATEMENT
STATUTORY RULES 2001 No. 312
Issued by the authority of the Minister for Health and Aged Care
Health Insurance Act 1973
Health Insurance (Pathology Services Table) Amendment Regulations 2001 (No. 4)
Section 133 of the Health Insurance Act 1973 (the Act) provides that the Governor-General may make regulations prescribing matters for the purposes of the Act.
The Act provides for payments of Medicare benefits in respect of professional services rendered to eligible persons. Section 9 of the Act provides that Medicare benefits shall be calculated by reference to the fees for medical services, including pathology services, set out in prescribed Tables.
Subsection 4A(1) of the Act provides that the regulations may prescribe a table of pathology services setting out items of pathology services; the amount of fees applicable in respect of each item; and rules for interpretation of the table. Subsection 4A(2) provides that, unless sooner repealed, regulations made under section 4A cease to be in force and are taken to be repealed on the day next following the 15th sitting day of the House of Representatives after the expiration of a period of 12 months commencing on the day on which the regulations are notified in the Gazette.
The Health Insurance (Pathology Services Table) Amendment Regulations 2001 (No. 4) amend the cervical cytology items on the Pathology Services Table of the Medicare Benefits Schedule, which commenced on 1 November 2001.
The current Medicare items for cervical cytology, which are underpinned by the Department's National Cervical Screening Program policy, provide that Medicare benefits can only be claimed when a `conventional' Pap smear has been performed. The `conventional' Pap smear involves the collection of cells from the cervix being placed directly onto a slide and examined under a microscope by a qualified cytotechnologist or pathologist.
There are currently a number of devices on the market that use other preparation and slide examination techniques which have yet to be properly assessed by the Medical Services Advisory Committee (MSAC). However, the broad wording of the current cervical cytology Medicare items 73053, 73055 and 73057 do not preclude the claiming of rebates for the use of these devices.
The changes to the items ensure that Medicare benefits are only claimable for the `conventional' Pap smear test until such time as these new devices are assessed by the MSAC, in line with Government policy for new medical services and technologies where public funding is being sought.
Details of the Regulations are provided at the Attachment.
The Regulations commence on 1 November 2001.
ATTACHMENT
Regulation 1 specifies the regulations as the Health Insurance (Pathology Services Table) Amendment Regulations 2001 (No. 4).
Regulation 2 prescribes a commencement date of 1 November 2001.
Regulation 3 prescribes the amendments to the Health Insurance (Pathology Services Table) Regulations 2001.
The amendments to the Pathology Services Table 2001 will incorporate changes to cervical cytology items 73053, 73055 and 73057.
Overview
The Health Insurance (Pathology Services Table) Amendment Regulations 2001 (No. 4) were enacted to address a gap in the Medicare Benefits Schedule concerning the definition and eligibility for rebates on cervical cytology services. Under the Health Insurance Act 1973, Medicare benefits are intended to cover professional services rendered to eligible persons, with the fees for these services, including pathology services, specified in prescribed tables. These regulations were introduced to ensure that rebates are only claimable for the 'conventional' Pap smear test until new devices and techniques are assessed by the Medical Services Advisory Committee (MSAC). The regulations were made by the authority of the Minister for Health and Aged Care, with the policy objective of aligning the provision of public funding for new medical services and technologies with the Department's National Cervical Screening Program policy. The changes aim to maintain the integrity of the Medicare system by restricting rebates to established and assessed methods of cervical cytology until such time as new technologies are evaluated and approved.
Scope and Application
The Health Insurance (Pathology Services Table) Amendment Regulations 2001 (No. 4) applies to entities and individuals involved in the provision and reimbursement of pathology services, particularly concerning cervical cytology, under the Medicare scheme in Australia. These regulations are made under the authority of the Health Insurance Act 1973, which governs the payment of Medicare benefits for medical services, including pathology. The regulations specifically target the amendment of the Pathology Services Table to ensure that Medicare benefits are only claimable for the conventional Pap smear test until new devices and techniques are assessed by the Medical Services Advisory Committee. The geographic reach of these regulations is nationwide, as they pertain to the national Medicare scheme administered by the Commonwealth of Australia. There are no stated exclusions or exemptions in these particular regulations, but they do establish thresholds and criteria for what constitutes eligible pathology services for the purpose of Medicare benefits. The application of these regulations can be further extended or refined through subordinate instruments as needed, although no such instruments are mentioned in the provided explanatory statement.
Key Provisions
The Health Insurance (Pathology Services Table) Amendment Regulations 2001 (No. 4) amend the cervical cytology items on the Pathology Services Table of the Medicare Benefits Schedule, which commenced on 1 November 2001. These regulations are made under section 4A of the Health Insurance Act 1973, which allows for the prescription of a table of pathology services and associated fees. Regulation 1 identifies these regulations as the Health Insurance (Pathology Services Table) Amendment Regulations 2001 (No. 4), and Regulation 2 sets the commencement date of 1 November 2001. Regulation 3 details the amendments to the Health Insurance (Pathology Services Table) Regulations 2001, specifically changing items 73053, 73055, and 73057 related to cervical cytology.
These regulations impose obligations on healthcare providers and pathology services to align their practices with the amended items. The amendments ensure that Medicare benefits for cervical cytology can only be claimed when a 'conventional' Pap smear, performed by placing cells from the cervix directly onto a slide and examined under a microscope by a qualified cytotechnologist or pathologist, is conducted. This requirement aligns with the Department's National Cervical Screening Program policy and Government policy for new medical services and technologies. Until such time as new devices using alternative preparation and slide examination techniques are assessed and approved by the Medical Services Advisory Committee (MSAC), only the 'conventional' Pap smear method qualifies for Medicare rebates.
The regulations also establish consequences for non-compliance. Healthcare providers and pathology services that do not adhere to the specified methods for claiming Medicare benefits may face financial penalties or other administrative actions. The Health Insurance Act 1973 includes provisions for civil and criminal penalties for non-compliance, although the specific penalties are not detailed in the explanatory statement. Generally, penalties may include fines or other financial repercussions, and in severe cases, criminal charges could be pursued. These measures are intended to ensure that public funding is used appropriately and in accordance with established medical practices and policies.